Slide 1: Q2 2026 Financial Results
Q2 2026 Financial Results July 30, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of histor
Slide 3: Q2 2026 Business Highlights
Q2 2026 Business Highlights (© 2026 CAREDX, INC. ALL SERVICE MARKS OR TRADEMARKS ARE OWNED OR LICENSED BY CAREDX, INC. ORITS AFFILIATES. ALL RIGHTS RESERVED.
Slide 4: Our Strategy for Delivering Profitable Growth
Our Strategy for Delivering Profitable Growth Delivering >15% volume growth and >20% revenue growth across each of the three last quarters in transplant #1 in Market High Disease Burden We address markets Clear leadership position Managed by a concentrated group of specialty providers where our core
Slide 5: Pipeline Programs: AlloHeme
Pipeline Programs AlloHeme, Advancing Toward Commercialization in Cell Therapy Blood-Based Relapse Monitoring for AML and MDS AlloHeme Clinical Validation presented at the 2026 Tandem Cell Therapy and Stem Cell Transplant Annual Meeting. Positive AlloHeme signal occurred a median of 41 days before A
Slide 6: Pipeline Programs: HistoMap Kidney
Pipeline Programs HistoMap Kidney: Molecular Tissue Profiling to Enhance Biopsy Interpretation & Patient Management Tissue-Based Molecular Test for Rejection Subtyping HistoMap Kidney Clinical Validation published in Transplantation: independent study of 138 biopsies demonstrated 85–93% concordance
Slide 7: Executing the NavDx Integration Strategy
Executing the NavDx Integration Strategy Focused on Accelerating Adoption, Embedding NavDx into Clinical Workflows, and Building a Scalable Commercial Infrastructure to Address a $4.5 Billion TAM Commercial Clinical Workflow Operational Execution Optimization Infrastructure Leveraging CareDx's Integ
Slide 8: Evidence Generation: Expanding Clinical Utility
Evidence Generation: Expanding Clinical Utility NavDx Continues to Generate Evidence Supporting Clinical Utility in HPV-Driven Cancers Predicting Response Defining Consensus in to Salvage Therapy CA H&N Consortium Clinical Practice New Data Presented — Featured NavDx AHNS Symposium Spotlighted the C
Slide 9: Evidence Generation: Extending Our Leadership
Evidence Generation: Extending Our Leadership New Data reinforces The Growing Role Of Molecular Testing To Identify Rejection And Inform Patient Management AlloSure Identifies Risk Early and Longitudinal AlloSure Trends Detects Ongoing Injury Predict Kidney Allograft Outcomes Featured AlloSure Kidne
Slide 10: Medicare Coverage Determination Reinforces the Role of Molecular Testing in Transplant Care
Medicare Coverage Determination Reinforces the Role of Molecular Testing in Transplant Care Final Coverage Policy Affirms Coverage For Surveillance Testing And Establishes Pathways For Continued Innovation Surveillance & Combined Molecular Molecular Tissue Future Organ For-Cause Testing Assessment D
Slide 11: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights
Slide 12: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Strong Revenue Growth, Margin Expansion, and Cash Generation • Total Revenue $132M 52% 17% 74% • Testing Revenue $100M Total Testing Services Total revenue growth YoY Non-GAAP Gross margin* • Testing Volume 58,000 volume growth YoY • 19% Adjusted EBITDA Margin* $25M $374
Slide 13: Q2 Revenue Performance
Q2 Revenue Performance Strong Execution Across The Portfolio Drove Growth Across All Businesses Total Revenue Testing Services Revenue Patient & Digital Revenue Lab Products Revenue $132M Volume +17% YoY to 58,000 $100M $19M $13M $12M $87M $13M $62M 52% 61% 50% 8% Growth YoY Growth YoY Growth YoY Gr
Slide 14: Q2 Non-GAAP Gross Margin & Adjusted EBITDA
Q2 Non-GAAP Gross Margin & Adjusted EBITDA Higher Revenue And Improved Operating Leverage Contributed To Strong Margin Performance Non-GAAP Gross Margin* Adjusted EBITDA* Drivers of improvement Drivers of improvement 74% 69% • Strong Testing Services $25M • Revenue growth and revenue growth favorabl
Slide 15: Q2 Cash Collection & Cash Flow From Operations
Q2 Cash Collection & Cash Flow From Operations Strong Cash Generation Reflects Profitable Growth and Operational Execution Cash Collection Cash Flow From Operations $136M $31M $91M 49% $10M +$21M Growth YoY Growth YoY Q2’25 Q2’26 Q2’25 Q2’26 15
Slide 16: Updated Full Year 2026 Guidance
Updated Full Year 2026 Guidance Range Previous Updated Revenue $447M to $465M $490M to $500M Adjusted EBITDA* $43M to $57M $66M to $78M Modeling assumptions • Testing services volume growth: 258k to 266k • Transplant 229k to 233k • Specialty Oncology 29k to 33k Midpoint Previous Updated • Out-of-per
Slide 17: 2026 Guidance: Divestiture and Acquisition Impact
2026 Guidance: Divestiture and Acquisition Impact Guidance Includes 1H Results For Lab Products And 2H Results For Naveris (“Specialty Oncology") Full Year Revenue Mix (2026 Shown at Midpoint of Guidance) • Sold Lab Products on June 30 th for $172M in consideration and recognized $113M gain on sale
Slide 18: Testing Revenue Per Test – 2025 vs Midpoint of 2026 Guidance
Testing Revenue Per Test – 2025 vs Midpoint of 2026 Guidance Revenue Per Test Expected To Increase 11% Including Specialty Oncology (18% Transplant Only) Revenue Per Test – Transplant Only (2026 at Midpoint of Guidance) Revenue Per Test (2026 Shown at Midpoint of Guidance) +18% +11% $1,627 $1,527 Ou
Slide 19: Appendix
Appendix (© 2026 CAREDX, INC. ALL SERVICE MARKS OR TRADEMARKS ARE OWNED OR LICENSED BY CAREDX, INC. ORITS AFFILIATES. ALL RIGHTS RESERVED.
Slide 20: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA (In thousands) Q2'26 Q2'25 GAAP net income (loss) $110,636 $(8,568) Gain on sale of lab products business (112,966) - Stock-based compensation expense 10,654 9,424 Acquisition related-amortization of purchased intangibles 529 1,589 Change in estimated fair value of
Slide 21: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA (In thousands) Q2'26 Q2'25 GAAP net income (loss) $110,636 $(8,568) GAAP net income margin 84% (10)% Gain on sale of lab products business (112,966) - Stock-based compensation expense 10,654 9,424 Acquisition related-amortization of purchased intangibles 529 1,589 C
Slide 22: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin (In thousands) Q2'26 Q2'25 GAAP total revenue $131,948 $86,679 GAAP cost of sales 34,966 28,658 GAAP gross profit 96,982 58,021 GAAP gross margin % 74% 67% Stock-based compensation expense 321 626 Restructuring costs - 338 Business development and portfolio op
Slide 23: Net Cash Provided by Operating Activities Reconciliation to Free Cash Flow
Net Cash Provided by Operating Activities Reconciliation to Free Cash Flow (In thousands) Q2'26 Q2'25 Net cash provided by operating activities (GAAP) $30,606 $9,898 Less: item not included in free cash flows Capital expenditures (GAAP) (1,858) (1,007) Free cash flow (non-GAAP) $28,748 $8,891 23
Slide 24: Reconciliation of GAAP and Non-GAAP operating expenses
Reconciliation of GAAP and Non-GAAP operating expenses (In thousands) Q2'26 Q2'25 GAAP operating expenses: Research and development $22,376 $16,830 Sales and marketing 33,441 24,279 General and administrative (72,058) 28,033 Total GAAP operating expenses $(16,241) $69,142 Non-GAAP operating expenses
Slide 25: Reconciliation of GAAP and Non-GAAP operating expenses
Reconciliation of GAAP and Non-GAAP operating expenses (In thousands) Q2'26 Q2'25 Research and development expenses reconciliation: GAAP research and development expenses 22,376 16,830 Stock-based compensation expense (1,121) (1,407) Business development and portfolio optimization expense* (504) - N
Slide 26: Contacts
Contacts Nina Deka INVESTOR RELATIONS investor@caredx.com Natasha Moshirian Wagner MEDIA RELATIONS nwagner@caredx.com CORPORATE HQ 8000 Marina Blvd, Brisbane, CA 94005